What Eptifibatide is
Eptifibatide is a cyclic peptide antiplatelet drug used in approved acute cardiovascular contexts.
Eptifibatide is grouped under Approved / Clinical on PeptideFactCheck because it is another reminder that peptide therapeutics cover major hospital medicines, not just internet niche compounds.
The useful starting point is to separate the molecule itself from the internet story around it. It is another reminder that peptide therapeutics cover major hospital medicines, not just internet niche compounds.
Why people keep looking it up
It is another reminder that peptide therapeutics cover major hospital medicines, not just internet niche compounds.
Eptifibatide is a cyclic peptide antiplatelet drug used in approved acute cardiovascular contexts.
Eptifibatide tends to stay in the conversation because it touches a familiar public theme: gp iib/iiia inhibitor, antiplatelet, and peptide medicine. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide therapeutic with direct human evidence.
Human trials and approved labeling support specific clinical uses.
Mechanism aligns with platelet GP IIb/IIIa inhibition.
Why this page carries the current tier: Approved peptide therapeutic with direct human evidence.
The current seed trail for Eptifibatide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a serious cardiovascular-drug context, not a lifestyle peptide.
FDA-approved eptifibatide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Eptifibatide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Eptifibatide is CID 448812. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 448812
- Formula
- C35H49N11O9S2
- Molecular weight
- 832.0
- InChIKey
- CZKPOZZJODAYPZ-LROMGURASA-N
Matched synonyms include Eptifibatide, 188627-80-7, Integrilin, Integrelin, Eptifibatida, DTXSID7046673, CHEBI:291902, NA8320J834.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Eptifibatide returns 35 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Eptifibatide returns 1392 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Eptifibatide
- Generic names
- EPTIFIBATIDE
- Routes
- INTRAVENOUS
- Application numbers
- ANDA206127
Indications and usage. 1 INDICATIONS AND USAGE Eptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) (1.1) Treatment of patients undergoing PCI (including intracoronary stenting) (1.2) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or n...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. (5.1) Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately. (5.2) 5.1 Bleeding Bleeding is the most common complication encountered during ep...
Contraindications. 4 CONTRAINDICATIONS Treatment with eptifibatide injection is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 da...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.